Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00702403 · ClinicalTrials.gov registry record · Phase 1
Nilotinib and Imatinib Mesylate After Donor Stem Cell Transplant in Treating Patients With ALL or CML
A Phase 1 study, sponsored by Fred Hutchinson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT00702403 is a Phase 1 study that has completed, run by Fred Hutchinson Cancer Center. The registered enrollment target is 40 participants.
The verdict
NCT00702403, a Phase 1 study, has completed, sponsored by Fred Hutchinson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
This phase I/II trial is studying the side effects and best way to give nilotinib when given alone or sequentially after imatinib mesylate after donor stem cell transplant in treating patients with acute lymphoblastic leukemia or chronic myelogenous leukemia. Nilotinib and imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Interventions
- DRUG imatinib mesylate
- OTHER pharmacological study
- DRUG nilotinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2008-08-14 |
| Est. Completion | 2013-12-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00702403
The ClinicalTrials.gov registry entry for NCT00702403 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fred Hutchinson Cancer Center, which has 483 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which imatinib mesylate is the first listed.
NCT00702403 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00702403 about?
NCT00702403 is a clinical study titled "Nilotinib and Imatinib Mesylate After Donor Stem Cell Transplant in Treating Patients With ALL or CML". This phase I/II trial is studying the side effects and best way to give nilotinib when given alone or sequentially after imatinib mesylate after donor stem cell transplant in treating patients with acute lymphoblastic leukemia or chronic myelogenous leukemia. Nilotinib and imatinib mesylate may stop...
What is the current status of trial NCT00702403?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2008-08-14. Estimated completion is 2013-12-01.
What interventions are being tested in trial NCT00702403?
The interventions under investigation include: imatinib mesylate (DRUG), pharmacological study (OTHER), nilotinib (DRUG).
Who is sponsoring clinical trial NCT00702403?
This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.